Patents Assigned to Schering Corporations
  • Selective D/Dreceptor antagonists for the treatment of obesity and CNS disorders
    Patent number: 7504391
    Abstract: The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: March 17, 2009
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, William J. Greenlee, Brian McKittrick, Jing Su, Zhaoning Zhu, Thavalakulamgara K. Sasikumar, Robert Mazzola, Li Qiang, Yuanzan Ye
  • Method of treating skin inflammation
    Patent number: 7501247
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: March 10, 2009
    Assignee: Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy
  • MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
    Publication number: 20090060865
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: July 28, 2008
    Publication date: March 5, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
    Patent number: 7498409
    Abstract: The present invention relates to novel screening methods for identifying agonists and antagonists of toll-like receptor (TLR) 7, TLR8 or TLR9. Methods are disclosed for identifying agonists and antagonists of TLR7, TLR8 or TLR9 using mutant TLR proteins containing deletions in one or more extracellular leucine rich regions (LRRs). Such agonists and antagonists have utility in the prevention, treatment and/or cure of various diseases and conditions, including cancer, virus infection, allergy, asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: March 3, 2009
    Assignee: Schering Corporation
    Inventors: Jaromir Vlach, Uzma Ayesha Hasan, Sandra Dollet
  • Fused ring NKantagonists
    Patent number: 7498438
    Abstract: A compound having the general structure shown in Formula 1: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: March 3, 2009
    Assignee: Schering Corporation
    Inventors: Dong Xiao, Anandan Palani, Cheng Wang, Hon-Chung Tsui, Neng-Yang Shih, Gregory A. Reichard
  • Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7498441
    Abstract: The present invention discloses compounds which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes. Compounds of the invention generally have the structure: where the substituents are as defined herein.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: March 3, 2009
    Assignee: Schering Corporation
    Inventors: Thavalakulamgara K. Sasikumar, Wen-Lian Wu, Duane A. Burnett, Li Qiang
  • Mammalian cytokine; related reagents
    Patent number: 7491500
    Abstract: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: February 17, 2009
    Assignee: Schering Corporation
    Inventors: Rene De Waal Malefyt, Helmut Fickenscher, Bernhard Fleckenstein, Andrea Knappe
  • Methods of Modulating Cytokine Activity; Related Reagents
    Publication number: 20090041718
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Application
    Filed: September 26, 2008
    Publication date: February 12, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • Thrombin receptor antagonists
    Patent number: 7488742
    Abstract: A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and binders to cannabinoid receptors.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: February 10, 2009
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia
  • Thrombin receptor antagonists
    Patent number: 7488752
    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: February 10, 2009
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia, Keith A. Eagen
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7488745
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: February 10, 2009
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Razia Rizvi, Aneta M. Micula, Robert Feltz
  • 17?-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
    Patent number: 7485645
    Abstract: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17?-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17?-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: February 3, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Yi-Tsung Liu, Ronald J. Doll, Anil Saksena, Viyyoor M. Girijavallabhan, Jonathan A. Pachter
  • Inhibitors of hepatitis C virus NS3/NS4a serine protease
    Patent number: 7485625
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: February 3, 2009
    Assignee: Schering Corporation
    Inventors: Francisco Velazquez, Srikanth Venkatraman, Ashok Arasappan, F. George Njoroge
  • mGluR1 antagonists as therapeutic agents
    Patent number: 7485648
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: February 3, 2009
    Assignee: Schering Corporation
    Inventors: Julius J. Matasi, Deen Tulshian, Duane A. Burnett, Wen-Lian Wu, Peter Korakas, Lisa S. Silverman, Thavalakulamgara K. Sasikumar, Li Qiang, Martin S. Domalski
  • High affinity ligands for nociceptin receptor ORL-1
    Patent number: 7485650
    Abstract: The compound of the formula or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds as nociceptin receptor inhibitors useful in the treatment of anxiety are disclosed.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: February 3, 2009
    Assignee: Schering Corporation
    Inventors: David G. Sawutz, Philippe Brianceau, Ana Bercovici, Ginny D. Ho, Deen Tulshian
  • Use of IL-17 Expression to Predict Skin Inflammation; Methods of Treatment
    Publication number: 20090028860
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
    Type: Application
    Filed: September 2, 2008
    Publication date: January 29, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy
  • Melanoma therapy
    Patent number: 7482014
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • C23 Polypeptides
    Patent number: 7482426
    Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Karin Franz-Bacon, Daniel M. Gorman, Terrill K. McClanahan
  • Fused tetracyclic mGluR1 antagonists as therapeutic agents
    Patent number: 7482360
    Abstract: In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimers disease.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, Wen-Lian Wu
  • Imidazole and benzimidazole derivatives useful as histamine Hantagonists
    Patent number: 7482468
    Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: n is 2-5; R is R3-aryl, R3-heteroaryl, R3-cycloalkyl, R3-heterocycloalkyl, alkyl, haloalkyl, —OR4, —SR4 or —S(O)1-2R5; R1 and R2 are H or optionally substituted phenyl or optionally substituted and X is —O— or —S—; or R1 and R2, together with the carbon atoms to which they are attached form optionally substituted and X is —O—, —S— or —NR7—; Z is and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I; also disclosed are methods of treating allergy, allergy-induced airway responses, congestion, obesity and metabolic syndrome using the compounds of Formula I, as well as combinations with other drugs useful for treating those diseases.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Wing C. Tom, Xiaohong Zhu